1. Home
  2. CTMX vs GLE Comparison

CTMX vs GLE Comparison

Compare CTMX & GLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • GLE
  • Stock Information
  • Founded
  • CTMX 2008
  • GLE 2018
  • Country
  • CTMX United States
  • GLE Hong Kong
  • Employees
  • CTMX N/A
  • GLE N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • GLE
  • Sector
  • CTMX Health Care
  • GLE
  • Exchange
  • CTMX Nasdaq
  • GLE NYSE
  • Market Cap
  • CTMX 444.3M
  • GLE 24.3M
  • IPO Year
  • CTMX 2015
  • GLE 2024
  • Fundamental
  • Price
  • CTMX $2.48
  • GLE $1.48
  • Analyst Decision
  • CTMX Strong Buy
  • GLE
  • Analyst Count
  • CTMX 2
  • GLE 0
  • Target Price
  • CTMX $5.00
  • GLE N/A
  • AVG Volume (30 Days)
  • CTMX 2.7M
  • GLE 309.3K
  • Earning Date
  • CTMX 08-07-2025
  • GLE 07-11-2025
  • Dividend Yield
  • CTMX N/A
  • GLE N/A
  • EPS Growth
  • CTMX 128.27
  • GLE N/A
  • EPS
  • CTMX 0.49
  • GLE 0.00
  • Revenue
  • CTMX $147,557,000.00
  • GLE $5,923,383.00
  • Revenue This Year
  • CTMX N/A
  • GLE N/A
  • Revenue Next Year
  • CTMX N/A
  • GLE N/A
  • P/E Ratio
  • CTMX $5.11
  • GLE $297.50
  • Revenue Growth
  • CTMX 23.81
  • GLE 26.42
  • 52 Week Low
  • CTMX $0.40
  • GLE $1.05
  • 52 Week High
  • CTMX $3.10
  • GLE $5.44
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 56.59
  • GLE N/A
  • Support Level
  • CTMX $2.15
  • GLE N/A
  • Resistance Level
  • CTMX $2.44
  • GLE N/A
  • Average True Range (ATR)
  • CTMX 0.24
  • GLE 0.00
  • MACD
  • CTMX -0.05
  • GLE 0.00
  • Stochastic Oscillator
  • CTMX 39.71
  • GLE 0.00

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About GLE GLOBAL ENGINE GROUP HOLDING LIMITED

Global Engine Group Holding Ltd offers integrated solutions by using ICT solutions to drive business outcomes and innovation. Its service offerings comprise services to telecom operators, including the one-stop shop purchase from telecom license application service to turnkey network setup as well as service outsourcing; business planning, development, technical and operations consulting programs structured to target the cloud computing and data center providers; system design, planning, development and operation services to technology companies; cloud platform deployment, IT system design and configuration services, maintenance services, data center colocation service and cloud service.

Share on Social Networks: